# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2015

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2015-07-31
- Accepted by EDGAR: Jul 31, 2015, 12:08 ET
- Period: 2015-06-30
- Accession: 0001193125-15-272414
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000119312515272414/d937821d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000119312515272414/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-04-01 to 2015-06-30 | $66.5m | us-gaap:SalesRevenueNet |
| Revenue | 6 months, 2015-01-01 to 2015-06-30 | $133.1m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2015-04-01 to 2015-06-30 | $41.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2015-01-01 to 2015-06-30 | $83.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2015-04-01 to 2015-06-30 | $25.1m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2015-01-01 to 2015-06-30 | $49.8m | us-gaap:GrossProfit |
| Operating income | 3 months, 2015-04-01 to 2015-06-30 | $1.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2015-01-01 to 2015-06-30 | $1.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-04-01 to 2015-06-30 | $710.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2015-01-01 to 2015-06-30 | $1.4m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-04-01 to 2015-06-30 | −$393.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2015-01-01 to 2015-06-30 | −$685.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-04-01 to 2015-06-30 | $781.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2015-01-01 to 2015-06-30 | $832.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-04-01 to 2015-06-30 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2015-01-01 to 2015-06-30 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-04-01 to 2015-06-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2015-01-01 to 2015-06-30 | $0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-04-01 to 2015-06-30 | 29,202,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2015-01-01 to 2015-06-30 | 29,103,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2015-01-01 to 2015-06-30 | $43.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2015-01-01 to 2015-06-30 | $36.4m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 6 months, 2015-01-01 to 2015-06-30 | $1.1m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2015-06-30 | $5.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-06-30 | $278.5m | us-gaap:AssetsCurrent |
| Total assets | at 2015-06-30 | $493.0m | us-gaap:Assets |
| Current liabilities | at 2015-06-30 | $111.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-06-30 | $230.1m | us-gaap:Liabilities |
| Long-term debt | at 2015-06-30 | $87.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-06-30 | $10.1m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2015-06-30 | $262.8m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 39,794 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

### RESULTS OF OPERATIONS

### Quarter Ended June 30:

| Net sales: | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Insecticides | $27,586 | $34,524 | $(6,938) |
| Herbicides/soil fumigants/fungicides | 17,451 | 13,926 | 3,525 |
| Other, including plant growth regulators | 12,755 | 8,929 | 3,826 |
| Total crop | 57,792 | 57,379 | 413 |
| Non-crop | 8,731 | 10,934 | (2,203) |
|  | $66,523 | $68,313 | $(1,790) |
| Cost of sales: |  |  |  |
| Insecticides | $18,401 | $21,063 | $(2,662) |
| Herbicides/soil fumigants/fungicides | 9,596 | 8,936 | 660 |
| Other, including plant growth regulators | 8,998 | 6,089 | 2,909 |
| Total crop | 36,995 | 36,088 | 907 |
| Non-crop | 4,407 | 6,165 | (1,758) |
|  | $41,402 | $42,253 | $(851) |
| Gross margin: |  |  |  |
| Insecticides | $9,185 | $13,461 | $(4,276) |
| Herbicides/soil fumigants/fungicides | 7,855 | 4,990 | 2,865 |
| Other, including plant growth regulators | 3,757 | 2,840 | 917 |
| Gross margin crop | 20,797 | 21,291 | (494) |
| Gross margin non-crop | 4,324 | 4,769 | (445) |
|  | $25,121 | $26,060 | $(939) |
| Gross margin crop | 36% | 37% |  |
| Gross margin non-crop | 49% | 44% |  |
| Total gross margin | 38% | 38% |  |
|  | **2015** | **2014** | **Change** |
| Net sales: |  |  |  |
| US | $43,842 | $50,094 | $(6,252) |
| International | 22,681 | 18,219 | 4,462 |
|  | $66,523 | $68,313 | $(1,790) |

18

Financial performance for the quarter ended June 30, 2015 included net sales of $66,523, which were down approximately 3% as compared to net sales of $68,313 for the second quarter of 2014. Our gross profit performance ended at $25,121 or 38% of net sales as compared $26,060 or 38% of net sales for the comparable quarter last year.

With respect to sales performance by category, net sales for our crop business remained flat at $57,792, as compared to $57,379 for the same period of the prior year, while net sales for non-crop products were down 20% at $8,731, as compared to $10,934 last year. From a geographic perspective, our domestic sales were down 12% and our international sales were up 24% during the comparable period. Included in international sales were immaterial revenues associated with the product lines acquired during the second quarter of 2015. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Second quarter 2015 financial performance was influenced by several factors, including weak re-stocking activity from distributors in the Midwest United States, and lower commodity price of corn causing some growers to minimize costs of their crop inputs. In addition to these factors in the corn market, reduced planted acres in cotton (as compared to the prior year) affected the sales of our cotton insecticide, Bidrin. Notwithstanding these factors, we saw improved sales performance in our Herbicide and Soil Fumigant product lines and higher year-over-year toll manufacturing activity, which contributed to improved manufacturing utilization and lower unabsorbed costs.

Net sales of our insecticide group for crop applications were down about 20%, to $27,586 as compared to $34,524 during the second quarter of 2014. Within this group, net sales of our granular soil insecticides (“GSIs”) were down approximately 9%, as compared to the comparable quarter in 2014. A significant portion of this sales performance was driven by a shift in the timing of sales for our Thimet® product used in sugar cane (from the second quarter in 2014 to the third quarter this year). Partially offsetting this drop was a significant increase in our Nemacur® product sold into a number of international markets. In our non-granular insecticide products, demand for our Bidrin® foliar insecticide used primarily for general plant bugs and particularly stink bugs defense in cotton, declined in line with the significant reduction in acres of U.S. cotton planted this year.

Within the group of herbicides/fungicides/fumigants, net sales for the second quarter of 2015 increased by approximately 25% to $17,451 from $13,926 in the same period of 2014. Net sales of our herbicide products rose significantly on the strength of our post-emergent corn herbicide, Impact®. Our soil fumigant sales were also significantly higher this year, driven in part by increased sales into U.S. vegetables markets, as compared to the prior period in 2014.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales increased by about 43% to $12,755, as compared to $8,929 in the second quarter of 2014. This performance was due largely to a quarterly sales increase in Folex® (our cotton defoliant / harvest aid) despite reduced cotton acres reflecting low customer inventory position, and finally a significant increase in toll manufacturing during the quarter.

Our non-crop sales ended the second quarter of 2015 at $8,731, which was 20% below net sales of $10,934 for the same period of the prior year. Despite strong net sales from our mosquito adulticide product, Dibrom® , we saw declines in our pest strip, pharmaceutical and Envance consumer pest spray product lines attributed to weather conditions.

Our cost of sales for the second quarter of 2015 was $41,402 or 62% of net sales. This compared to $42,253 or 62% of net sales for 2014. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. During the three month periods ended June 30, 2015 and 2014, raw material purchase prices remained flat. As a percentage of sales, raw materials increased from 37.5% in 2014 to 40.0% in 2015. This increase was driven by the increased proportion of international sales, which represented 34.0% of sales in the quarter ended June 30, 2015 and 27.0% in the comparable quarter of prior year. Labor and burden costs also increase from 14.0% in 2014 to 16.5% in 2015. This effect was driven by the significant shift from domestic to international sales and also higher levels of tolling product sales (both international and tolling product sales have higher cost of goods when compare to domestic sales).

For the three months ended June 30, 2015, the cost of running our U.S. factories was about 7.0% higher than costs in 2014. A primary driver for the increase is associated with the tolling activity. Offsetting this increase, factory output and associated overhead recovery was 61% higher than the same period of 2014. The overall factory performance added $3,017 or 4.5% to the gross margin performance for the quarter of 2015 and offset the adverse mix impacts described above. As a result, our gross profit ended at 38% of sales, which was flat as compared to the same period of the prior year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses decreased by $1,415 to $23,922 for the three months ended June 30, 2015, as compared to the same period in 2014. The differences in operating expenses by department are as follows:

|  | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Selling | $6,934 | $8,805 | $(1,871) |
| General and administrative | 7,069 | 6,068 | 1,001 |
| Research, product development and regulatory | 5,275 | 5,040 | 235 |
| Freight, delivery and warehousing | 4,644 | 5,424 | (780) |
|  | $23,922 | $25,337 | $(1,415) |

- Selling expenses decreased $1,871 over the same quarter of the prior year. The main driver for the decrease is the reduction in advertising and promotional activities.
- General and administrative expenses increased by $1,001 to $7,069, as compared to $6,068 for the same period of the prior year. The main drivers for the increase are related to increased stock based compensation and amortization expense from the product line acquisitions.
- Research, product development costs and regulatory expenses increased by $235 to $5,275, as compared to the same period of the prior year. In the three months ended June 30, 2015, the increase in our spending on long term business development projects was offset by regulatory compliance that was driven by timing on our regulatory compliance studies.
- Freight, delivery and warehousing costs decreased by $780 to $4,644, as compared to the same period of 2014. As a percentage of sales, freight ended at 7.0% of sales for the three months ended June 30, 2015 as compared to 7.9% for the same period of the prior year. The main drivers for this decrease are related to an increase in sales of products with low freight costs and products where buyers bear freight charges.

Interest costs, net of capitalized interest, were $662 in the three months ended June 30, 2015, as compared to $844 in the same period of 2014. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Q2 2015 Average Debt | Interest Expense | Interest Rate | Q2 2014 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Average revolving line of credit | $105,796 | $527 | 1.9% | $111,779 | $684 | 2.4% |
| Notes payable | 1,404 | 68 | — | 170 | 1 | — |
| Interest income | — | (1) | — | — | (3) | — |
| Amortization of deferred loan fees | — | 60 | — | — | 58 | — |
| Amortization of other deferred liabilities | — | 38 | — | — | 105 | — |
| Other interest expense | — | 18 | — | — | 12 | — |
| Subtotal | $107,200 | $710 | 2.6% | $111,949 | $857 | 3.0% |
| Capitalized interest | — | (48) | — | — | (13) | — |
| Total | $107,200 | $662 | 2.5% | $111,949 | $844 | 3.0% |

The Company’s average overall debt for the three months ended June 30, 2015 was $107,200 as compared to $111,949 for the three months ended June 30, 2014. In fact, the Company reduced average overall debt to $85,631 as a result of collecting receivables, which were due towards the end of the second quarter. Offsetting this reduction, the Company principally used cash in the purchase of product lines. During the quarter we reduced working capital by $27,275 and decreased our usage of revolving debt as a result. Also during the quarter we acquired two new product lines funded partly by a seller note and partly by increasing usage of revolving debt. As can be seen from the table above, our effective bank interest rate was 1.9% for the three months ended as compared to 2.4% in 2014. This improvement is driven by the terms of the New Credit Agreement and the expiration of the interest rate swap contract that was held in 2014.

Income tax benefit increased by $233 to end at a benefit of $393 for the three months ended June 30, 2015 as compared to a benefit of $160 for the comparable period in 2014. The effective tax rate for the quarter was (73.2%) (which was a tax benefit), as compared to 132.2% (which was also a tax benefit) in the same period of the prior year. The change in effective tax rate is primarily due to comparatively higher earnings in our international tax jurisdictions that are taxed at a comparatively lower rate than the U.S. statutory rates and a loss in the U.S. The effective tax rate for the three months ended June 30, 2015 is based on the financial statements for the six months ended June 30, 2015. It became increasingly difficult to estimate a reliable annual effective tax rate for the 2015 financial year because of the uncertainty in forecasting taxable income or loss for the remainder of the year for each of our domestic and international operations. Significant changes in our estimated annual effective tax rate could result from changes in forecasts or actual results for either our domestic or international operations. Since an estimated annual effective tax rate under these circumstances would not provide a meaningful estimate, an actual year-to-date effective tax rate is the best estimate of the annual tax rate.

During the three months ended June 30, 2015 we recognized a loss of $191 on our investment in TyraTech, as compared to recognizing a loss of $68 during the three months ended June 30, 2014.

Non-controlling interest in Envance for the three months ended June 30, 2015 decreased to $42 as compared to $174 for the three months ended June 30, 2014. Non-controlling interest represents the share of net loss that is attributable to TyraTech’s share, the minority stockholder, of our majority owned subsidiary, Envance. During the quarter ended June 30, 2015, the Company reached agreement with the minority shareholder in Envance (TyraTech) to reduce that company’s minority shareholding from 40% to 13%.

Our net income for the second quarter of 2015 was $781 or $0.03 per diluted share ($0.03 per share—basic) as compared to $145 or $0.01 per diluted share ($0.01 per share—basic) in the same quarter of 2014.

### Six Months Ended June 30:

| Net sales: | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Insecticides | $61,945 | $80,961 | $(19,016) |
| Herbicides/soil fumigants/fungicides | 39,291 | 36,857 | 2,434 |
| Other, including plant growth regulators | 16,077 | 12,736 | 3,341 |
| Total crop | 117,313 | 130,554 | (13,241) |
| Non-crop | 15,775 | 18,854 | (3,079) |
|  | $133,088 | $149,408 | $(16,320) |
| Cost of sales: |  |  |  |
| Insecticides | $41,005 | $51,651 | $(10,646) |
| Herbicides/soil fumigants/fungicides | 23,186 | 22,406 | 780 |
| Other, including plant growth regulators | 10,367 | 9,524 | 843 |
| Total crop | 74,558 | 83,581 | (9,023) |
| Non-crop | 8,759 | 10,862 | (2,103) |
|  | $83,317 | $94,443 | $(11,126) |
| Gross margin: |  |  |  |
| Insecticides | $20,940 | $29,310 | $(8,370) |
| Herbicides/soil fumigants/fungicides | 16,105 | 14,451 | 1,654 |
| Other, including plant growth regulators | 5,710 | 3,212 | 2,498 |
| Gross margin crop | 42,755 | 46,973 | (4,218) |
| Gross margin non-crop | 7,016 | 7,992 | (976) |
|  | $49,771 | $54,965 | $(5,194) |
| Gross margin crop | 36% | 36% |  |
| Gross margin non-crop | 44% | 42% |  |
| Total gross margin | 37% | 37% |  |
|  | **2015** | **2014** | **Change** |
| Net sales: |  |  |  |
| US | $93,064 | $108,050 | $(14,986) |
| International | 40,024 | 41,358 | (1,334) |
|  | $133,088 | $149,408 | $(16,320) |

21

Overall financial performance including net sales and net income for the six month period ended June 30, 2015 showed a decline as compared to the same period in 2014. Net sales for the period were down approximately 11% to $133,088 compared to $149,408 for the first half of 2014. Our gross profit performance ended at $49,771 or 37% of net sales, as compared to $54,965 or 37% of net sales for the comparable prior period.

With respect to specific categories, net sales for our crop business were $117,313, down by approximately 10% from $130,554 in 2014, while net sales for non-crop products were $15,775, down by about 16% from $18,854, in the comparable period of the prior year. Our international sales were also down slightly at $40,024, as compared to $41,358 for the same period of the prior year. A more detailed discussion of general market conditions and sales performance by category of products appears below.

Over the course of the first half of 2015, the Company continued to experience soft demand for its corn products. This was primarily due to below normal re-stocking procurement by the Midwest channel of distribution, as it continued to work through surplus inventories. Additionally, the lower commodity price of corn tended to cause growers to trim their input costs where possible, including some reduced usage of at-plant insecticides. Furthermore, 2015 saw reduced planted acreage in U.S. cotton, which resulted in softer demand for our cotton insecticide Bidrin (see below).

Net sales of our insecticides used in crop applications for the six months ended June 30, 2015 were down about 23% to $61,945, as compared to $80,961 during the first half of 2014. Within this category, net sales of our granular soil insecticides (“GSIs”) were down approximately 21% relative to the comparable period in 2014. Demand for our Thimet product remained stable for use on the U.S peanut crop, but there was a shift in this year’s procurement pattern for sugar cane from the second quarter last year to the third quarter this year. Net sales of our non-GSI insecticides for crop applications were lower during the first half of 2015 as compared to the same period of the prior year, largely due to reduced US cotton acres driving lower demand for our foliar insecticide Bidrin®.

Within the group of herbicides/fungicides/fumigants, net sales for the first half of 2015 were $39,291, approximately 7% higher than the $36,857 recorded in the first half of 2014. While net sales of our primary corn herbicide Impact declined moderately as a result of some prior-year inventory carryover, our soil fumigants net sales increased significantly during the first half of the year.

Within the group of other products (which includes plant growth regulators, molluscicides and tolling activity), our net sales increased by about 26% to $16,077, as compared to $12,736 in the first half of 2014. Approximately one-third of the increased sales resulted from additional sales of our cotton harvest aid, Folex, which happened despite overall reduced cotton acres. The balance of the increased sales was driven by higher sales of our snail control granules and our toll manufacturing revenues.

Our non-crop sales for the first half of 2015 were $15,775, down 16% from $18,854 for the same period of the prior year. While sales of our mosquito adulticide Dibrom® remained essentially level with the prior midyear result, our Pest Strip business, pharmaceutical sales and consumer pest spray revenues were all lower in the first six months of 2015, as compared to the similar period in 2014.

Our cost of sales for the first six months of 2015 was $83,317 or 63% of net sales, compared to $94,443 or 63% of net sales for 2014. The Company aggregates a number of key variable, semi-variable and fixed cost components within reported cost of sales. During the six months ended June 30, 2015, raw material purchase prices remained flat. This was also the case for the six month period of the prior year. As a percentage of sales, material costs increased to 39.0% in 2015, as compared to 38.0% in 2014. This was driven by the increase in international sales to 30.0% of sales for the six months ended June 30, 2015, from 28.0% for comparable period of the prior year. Furthermore, labor and burden overhead increased from 14.5% in 2014 to 16.0% in 2015. This was caused by the change in mix of international and domestic sales (international sales generate lower margins and relatively higher cost of goods). These factors had the impact of reducing gross margin before factory performance by 2.5%.

Factory performance has been much improved in the first two quarters of 2015, as compared to the same period of 2014. Actual costs of running the four U.S. factories reduced by 3.5% as a result of strong efforts on improving efficiency. At the same time, factory output improved by 32.0% as a result of having carefully managed output in the second half of 2014 and thus allowing selective inventory building to occur in the first half of 2014. Lower factory cost and improved activities led to overhead recovery that resulted in approximately 2.5% better margin performance, which had the impact of offsetting the adverse mix factors mentioned. As a result, our gross profit ended flat at 37% of sales, as compared to the same period of the prior year.

It should be noted that, when making comparisons with other companies’ financial statements, the Company reports distribution costs in operating expenses and not as part of cost of sales.

Operating expenses decreased by $2,270 to $48,266 for the six months ended June 30, 2015, as compared to the same period in 2014. The differences in operating expenses by department are as follows:

|  | 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Selling | $14,309 | $16,976 | $(2,667) |
| General and administrative | 13,410 | 12,798 | 612 |
| Research, product development and regulatory | 10,112 | 9,773 | 339 |
| Freight, delivery and warehousing | 10,435 | 10,989 | (554) |
|  | $48,266 | $50,536 | $(2,270) |

- Selling expenses for the period decreased by $2,667 to end at $14,309, as compared to the first six months of 2014. The main driver for the overall decrease in selling expenses was costs associated with advertising and promotional activities.
- General and administrative expenses increased by $612 to end at $13,410, as compared to $12,798 for the same period of 2014. The main drivers for the increase are related to increases in stock based compensation and amortization expense from the product line acquisitions in the second quarter.
- Research, product development costs and regulatory expenses increased by $339 to end at $10,112, as compared to $9,773 for the same period of the prior year. The main drivers were increased costs incurred in our formulation chemistry and business development activities, offset by reduced expenditures in product defense.
- Freight, delivery and warehousing costs for the six months ended June 30, 2015 were $10,435 or 7.8% of sales as compared to $10,989 or 7.4% of sales for the same period in 2014. The main drivers for the decrease are related to increase in sales of products with low freight costs and products where buyers bear freight charges.

Interest costs, net of capitalized interest, were $1,303 in the six months of 2015, as compared to $1,457 in the same period of 2014. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2015 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2014 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Average revolving line of credit | $106,120 | $1,043 | 2.0% | $93,728 | $1,173 | 2.5% |
| Notes payable | 851 | 69 | — | 178 | 3 | — |
| Interest income | — | (1) | — | — | (3) | — |
| Amortization of deferred loan fees | — | 166 | — | — | 117 | — |
| Amortization of other deferred liabilities | — | 85 | — | — | 174 | — |
| Other interest expense | — | 28 | — | — | 24 | — |
| Subtotal | $106,971 | $1,390 | 2.5% | $93,906 | $1,488 | 3.1% |
| Capitalized interest | — | (87) | — | — | (31) | — |
| Total | $106,971 | $1,303 | 2.4% | $93,906 | $1,457 | 3.1% |

The Company’s average overall debt for the six months ended June 30, 2015 was $106,971 as compared to $93,906 for the six months ended June 30, 2014. During the six months ended June 30, 2015, we worked down working capital and associated revolving debt. Offsetting this performance, we increased debt to fund product line acquisitions. In the comparable of 2014, we increased revolving debt as working capital increased in response to a slowdown in our Midwest market. As can be seen from the table above, our effective bank interest rate was 2.0% for the six months ended June 30, 2015 as compared to 2.5% for the same period in 2014. This is driven by the new credit facility agreement and the expiration of the interest rate swap contract that was held in 2014.

Income taxes decreased by $1,541 to end at a benefit of ($685) for the six months ended June 30, 2015, as compared to an expense of $856 for the comparable period in 2014. The effective tax benefit rate for the period was (339.1%) as compared to a tax expense rate of 27% in the same period of the prior year. The change in the effective tax rate is primarily due to comparatively higher earnings in our international tax jurisdictions that are taxed at a comparatively lower rate than the U.S. statutory rates and a loss in the U.S. The effective tax rate for the six months ended June 30, 2015 is based on the financial statements for the six months ended June 30, 2015. It became increasingly difficult to estimate a reliable annual effective tax rate for our company for the year because of the uncertainty in forecasting taxable income or loss for the remainder of the year for each of our domestic and international operations. Significant changes in our estimated annual effective tax rate could result from changes in forecasts or actual results for either our domestic or international operations. Since an estimated annual effective tax rate under these circumstances would not provide a meaningful estimate, an actual year-to-date effective tax rate is the best estimate of the annual tax rate.

During the six months ended June 30, 2015, we recognized a loss of $191 on our investment in TyraTech, as compared to a loss of $396 during the six months ended June 30, 2014. The loss recognized during the six months ended June 30, 2014 is exclusive of a gain of $256 related to the sale by TyraTech of additional stock.

Non-controlling interest in Envance for the six months ended June 30, 2015 decreased to $136 as compared to $328 for the six months ended June 30, 2014. Non-controlling interest represents the share of net loss that is attributable to TyraTech, the minority shareholder, of our majority owned subsidiary, Envance.

Our net income for the first six months of 2015 was $832 or $0.03 per diluted share ($0.03 per share—basic) as compared to $2,304 or $0.08 per diluted share ($0.08 per share—basic) in the same period of 2014.

### LIQUIDITY AND CAPITAL RESOURCES

The Company generated $43,824 of cash in operating activities during the six months ended June 30, 2015. This compared with using $29,039 in the same period of last year. Net income of $696, the sum of non-cash depreciation, amortization of intangibles, other assets and discounted future liabilities equaled $10,752 and stock based compensation and other non-cash items of $2,669 provided a net cash inflow $14,117 compared to $14,858 for the same period last year.

During the six months ended June 30, 2015, the Company reduced receivables by $11,075 and offset that with an increase in VAT receivable of $2,100 associated with a product line acquisition (which we expect to recover during the third quarter). This compares with an increase in trade receivables of $1,025 during the same period of 2014.

Our inventories have reduced by $397 during the six month period of 2015, as compared to increasing by $35,410 during the same period of the prior year. This 2015 performance reflects the efforts that the Company has put into controlling the balance of manufacturing and demand while continuing to correct channel inventory levels. As of the balance sheet date, June 30, 2015, we believe our inventories are valued at lower of cost or market.

During the six months ended June 30, 2015, deferred revenues increased by $3,611, as compared to a decrease of $2,276 for the same period of the prior year. The increase in deferred revenues reflects individual customer decisions to take up related incentive programs and pay in advance for product deliveries later in the growing season.

The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th each year. During the six months ended June 30, 2015, the Company made accruals in the amount of $25,673. Programs are primarily paid out to customers either in the final quarter of the fiscal year or the first quarter of the next fiscal year. However, there are some programs that are paid more frequently or that have different settlement dates that reflect particular growing seasons. During the first six months of 2015, the Company made payments in the amount of $8,616. Payments are not generally significant in the second and third quarters of each financial year. During the six months ended June 30, 2014, the Company accrued $30,355 and made payments in the amount of $9,626.

Finally, our prepaid and other assets remained flat, tax receivable increased by $878, accounts payable reduced by $392 and we made $899 in deferred payments associated with product line acquisitions completed in 2010. In aggregate, this amounted to $2,169 outflow. During the same period of 2014, these items amounted to a $17,510 outflow.

The Company is working to manage its capital spending closely during this slow trading period and utilized $3,480 during the six months ended June 30, 2015, compared to utilizing $3,954 during the same period of 2014. This is primarily driven by capital spending in our factories. Also during the first six months of 2015, the Company completed two acquisitions of product lines and spent a total of approximately $36,000 on those transactions. Furthermore, the Company increased its ownership share of its Envance subsidiary by paying $125 to its joint venture partner TyraTech. There were no investments or intangible asset purchases in the same period of the prior year.

Financing activities used $3,193 during the six months ended June 30, 2015, compared to providing $30,412 in the same period of the prior year. This included a pay down of $11,000 against our senior credit facility, in addition to the increase in deferred loan fees of $120. During the period we increased our other notes payable in the amount of $10,000 related to one product line acquisition and made immaterial scheduled deferred payments related to product acquisitions. Further, the Company made dividend payments in the amount of $1,141. Finally, the Company utilized $308 upon vesting of shares and the exercise of stock options and received $275 from the sale of common stock under its Employee Stock Purchase Plan (including associated tax benefits of $7), as compared to receiving $1,458 during the first six months of 2014.

The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the balance sheets at June 30, 2015 and December 31, 2014. These are summarized in the following table:

| Indebtedness $000’s | June 30, 2015 Long- term | Short- term | Total | December 31, 2014 Long- term | Short- term | Total |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit | $88,400 | $— | $88,400 | $99,400 | $— | $99,400 |
| Deferred loan fees | (804) | — | (804) | (850) | — | (850) |
| Notes payable | 18 | 10,072 | 10,090 | 55 | 71 | 126 |
| Total Indebtedness | $87,614 | $10,072 | $97,686 | $98,605 | $71 | $98,676 |

The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of June 30, 2015 the Company met all covenants in that credit facility.

At June 30, 2015, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $27,101 under the credit facility agreement. This compares to an available borrowing capacity of $64,057 as of June 30, 2014. This decrease in borrowing availability arises from reduced financial performance (as measured in EBITDA) for the trailing twelve month period and increased borrowings associated with product line acquisitions.

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

In April 2015, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, *Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.* This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. ASU 2015-03 is effective for financials statement issued for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company evaluated the impact and has elected an early adoption of this update in the quarter ended June 30, 2015. This change was immaterial to the condensed consolidated financial statements.

In August 2014, FASB issued ASU2014-15, *Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.* This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligations as they become due within 12 months of the date of the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. Upon adoption, the Company will follow the guidance in this ASU when assessing going concern.

In June 2014, FASB issued ASU 2014-12, *Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force*. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.

In May 2014, the FASB issued ASU 2014-09, *Revenue from Contracts with Customers*. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). In April 2015, the FASB voted to defer the effective date of this update to December 15, 2017. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018 or its impact on our consolidated financial statements.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements for inclusion in the American Vanguard published financial statements. In the Company’s consolidated Form 10-K for the financial year ended December 31, 2014, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2014.

## Market risk

As filed, 1,409 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2014. The Company used derivative financial instruments for trading purposes to protect trading performance from exchange rate fluctuations on material contracts.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,068 characters.

As of June 30, 2015, the Company has established a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2015, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer have concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 410 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2014, filed on February 27, 2015. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors.

Filed Jul 31, 2015.
Source: SEC EDGAR, the filing index for accession 0001193125-15-272414. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
